Check out what we have in store for you in the March Newsletter
Dear Hepatitis C Advocaters,
The March issue is ready for your viewing. Before we get to this month’s newsletter I want to bring to your attention a new site within our website group:
The Hepatitis C Advocate Pipeline & Conference Coverage site: on this site you will find information about drugs in development to supplement our Drug Pipeline, and we will have coverage from major conferences (EASL and AASLD). We will also post abstracts about hepatitis with brief editorial comments. The new site will include a search engine option as well as a drop down menu “categories” that have been indexed by a list of major topics. We will notify our website audience of new postings via our Facebook and Twitter accounts.
The new site will join our other sites within our website group including:
Hepatitis C Medication site that lists all the approved direct-acting medications to treat chronic hepatitis C searchable by genotype and drug name, and
Clinical Trial Reference Guide that lists clinical trials studies for hepatitis C patients by countries and we have updated the clinical trials in America by state
The March 2017 HCV Advocate newsletter has the following news articles:
- HealthWise – Why We Need to Treat Everyone Who Has Hepatitis C by Lucinda K. Porter, RN – Lucinda explores how to eliminate hepatitis C in this thought-provoking article.
- Under The Umbrella—The Pros and Cons of Learning about Hepatitis C on the Internet by Matthew Zielske—Matthew writes about the pros and cons of educating ourselves and others about hepatitis C on the internet.
- SnapShots by Alan Franciscus.In this month’s column, I write about three studies—the new liver chemistry guidelines issued, potential liver injury from herbal and dietary supplements, and an analysis about the treatment using Zepatier in people with compensated cirrhosis.
- The Drug Pipeline has been pretty quiet this month with the exception of the news that AbbVie’s two drug combination of glecaprevir plus pibrentasvir to treat all genotypes (pan-genotypic) had been granted an FDA priority review – meaning that the drug approval process will be speeded up.
- What’s Up! – In this month notice we have updated the following fact sheets:
Alan and the staff of the HCV Advocate
Check out what we have in store for you in the December Newsletter
It’s hard to believe that it’s December and 2017 is right around the corner. It’s been a busy year at the HCV Advocate and this month’s issue is no exception. Lucinda K. Porter RN and I have each picked some of our favorite abstracts from this year’s AASLD’s Liver Meeting. Matthew Zielske’s article continues on the theme of research to discuss turning research and education into practice.
- The Five by Alan Franciscus – I have picked five abstracts that I think are some of the most interesting including alcohol and treatment, HBV reactivation during and after HCV treatment, patient descriptions of fatigue (my favorite), curing HCV and diabetes, and the cost of generic direct-acting antiviral medications.
- HealthWise by Lucinda K. Porter—AASLD – Lucinda has picked various abstracts such as payer treatment restrictions, pre-existing liver disease treatment and outcomes of breast cancer, hepatitis C reactivation in patients with cancer, alcohol and treatment outcome, fatigue, HAV and HBV vaccination in people with liver disease, and surveillance and screening of liver cancer.
- Under the Umbrella by Matthew Zielske –The challenges of proving what we know – Matthew writes about the importance of communication and some of the discrimination that people face when seeking information and medical care.
- HCV Advocate Pipeline has been updated with phase 2 information about AbbVie’s combination of glecaprevir plus pibrentasvir to treat genotype 1, 3,4, 5, and 6. Hint – very high cure rates.
- What’s Up!
- Check out our new Easy C fact sheets:
- We have updated our HCSP fact sheet:
Coming Next Month
- The Top News Stories of 2016
- A New Fact Sheet Series: Harm Reduction
Many thanks for your continued support,
Alan and the HCV Advocate team
Check out what we have in store for you in the November Newsletter
Here we are in the fall and only days away from the election—finally! Anyway, this issue of the HCV Advocate newsletter is, in my opinion, one of our best. I hope you think so too!
Please find the following articles:
- HealthWise – Talking to Your Doctor About Hepatitis C Treatment, Getting What’s Best for You by Lucinda K. Porter, RN — Lucinda discusses the importance of working with your doctor, how to fight insurance denials, helpful resources, and other important information.
- HCV Drugs by Alan Franciscus — I discuss two studies—the first one is about Gilead’s salvage therapy to treat the small percentage of people who do not respond to the current standard of care. The second study is an AbbVie study that treated HCV genotype 1b patients for 8 weeks that resulted in very high cure rates.
- Snapshots by Alan Franciscus — I reviewed two studies: The first one is a study conducted in the Veterans Affairs National Health Care System that evaluated all of the current (at that time) direct-acting antivirals (DAAs) medications to understand the cure rates and the ‘real-world’ results vs. results from the clinical trials.
- Under the Umbrella HCV Community Education – Teaching and Learning by Matthew Zielske—Matthew shares his ideas and experiences as an educator. Matthew has conducted our Train-the-Trainer Workshops in Indiana and Kentucky and we hope to expand the workshops throughout the United States in 2017.
- HCV Drug Pipeline Our Drug Pipeline has been updated with the information about the Gilead data from this month’s newsletter.
- What’s Up!
- Check out our new Easy C fact sheet on the importance of testing for hepatitis B before initiating HCV direct-acting antiviral therapy.
- We have also added many resources to our Trainers page including 2 slide sets—a short presentation and the longer that one we include in our Train-the-Trainer workshops. We also have a list of resources.
Don’t forget to join us for coverage of the Liver Meeting. We will be covering it on our News and Pipeline blog and in the December 2016 and January 2017 HCV Advocate Newsletter.
Alan and the staff of the HCV Advocate Newsletter
Check out what we have in store for you in the October Newsletter
As the election draws near, it is important that everyone, regardless of political leanings, register and vote in your local, state and national election. This election is probably the most important election of our lifetime and the outcome will affect almost every area of our lives for years to come including hepatitis C healthcare, treatment, and drug therapy.
This month’s newsletter is packed with important information that everyone with hepatitis C should review:
- HCV Drugs by Alan Franciscus – I reviewed two studies: The first study is about the final results of the treatment of Odalasvir plus AL-335 with and without simeprevir to treat HCV genotype 1 treatment naïve patients for 6 or 8 weeks. The second review is the mind-boggling outcomes of a study that used a 2-day response guided protocol to treat people for 3 weeks that produced 100% cure rates.
- Snapshots by Alan Franciscus—I reviewed two studies: The first one is a study conducted in the Veterans Affairs National Health Care System that evaluated all of the current (at that time) direct-acting antivirals (DAAs) medications to understand the cure rates and the ‘real-world’ results vs. results from the clinical trials.
- HealthWise – How I Nearly Outed Someone’s Hepatitis C Status: A Cautionary Tale by Lucinda K. Porter, RN—Lucinda discusses privacy issues that we are all concerned about in the age of Facebook, Twitter, and the other social media/internet and how to combat privacy issues and stigma.
- Under the Umbrella—No Man is an Island: Part 2, Hepatitis C in Rural Southern Indiana—Matthew continues his saga about HCV with an emphasis on jails and prisons including what can be done to provide education and support to improve the health outcomes of inmates living with hepatitis C and therefore the entire community of hepatitis C.
- Monthly Drug Pipeline has been updated with a link to the article about the Janssen story in this month’s HCV Advocate.
- What’s Up!
Check out what we have in store for you in the September Newsletter
This month’s HCV Advocate newsletter includes:
- HCV Advocate Clinical Trials Reference Guide is now available to search for hepatitis C (HCV) and HIV/HCV coinfected trials. There are instructions on the front page of the Reference Guide to search for clinical trials. The Reference Guide will be updated on a regular basis.
- A companion piece—How to Evaluate a Clinical Trial—provides simple tips to help decide whether a particular clinical trial is right for you.
- HealthWise—The Tragic Tale of Hemophilia, Hepatitis, and HIV by Lucinda K. Porter, RN—Lucinda probes the history of ‘bad blood’ scandals, and the people and communities affected.
- Under the Umbrella—No Man is an Island: Part 1, Hepatitis C in Rural Southern Indiana by Matthew Zielske. Matthew discusses the HIV and hepatitis C outbreak in Indiana and the community response.
- HCV Advocate Monthly Pipeline has been updated with more information about the results from Gilead’s phase 2 study of sofosbuvir, velpatasvir and voxilaprevir to treat hepatitis C.
- What’s Up!
- We have updated the following fact sheets:
- HCSP Fact Sheets—HCV Populations:
- African Americans and hepatitis C
- Genotype 2
- Genotype 3
- Easy C:
- Easy B’s
- HBV Transmission and Prevention – the entire series of our hepatitis B fact sheets have been reviewed and updated.
- HCV Medications Blog has been updated with information about Viekira XR a time-released formulation of Viekira Pak that was recently approved by the Food and Drug Administration.
Alan and the staff of the HCV Advocate
Get tested, Get Treated, Get Cured